Experimental flavonoid research compound · Fact sheet
7,8-Dihydroxyflavone
Also known as 7,8-DHF · Tropoflavin
7,8-Dihydroxyflavone is a flavonoid studied in preclinical neurotrophic-signaling models. Its proposed direct TrkB mechanism is disputed, and human memory or neuroprotection benefits are not established.
What is 7,8-Dihydroxyflavone?
TrkB is a receptor activated by brain-derived neurotrophic factor, or BDNF. Some papers describe 7,8-DHF as a small-molecule BDNF mimic.
Independent assay work has challenged whether it reproduces BDNF-like TrkB activation.
Benefits & claims
Readers encounter 7,8-Dihydroxyflavone in discussions of cognition, mood or mental fatigue. The relevant study population and outcome determine whether those claims are supported.
What the evidence supports
- The original experiments reported neurotrophic and receptor-related activity.
- Mouse Alzheimer-model studies reported selected memory or synaptic effects.
- Uncertainty about the mechanism and lack of established human outcomes prevent confident clinical claims.
Research areas
- Cognition and memory
- Neurologic or psychiatric research
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for 7,8-Dihydroxyflavone. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- TrkB is a receptor activated by brain-derived neurotrophic factor, or BDNF. Some papers describe 7,8-DHF as a small-molecule BDNF mimic.
Formulation differences
- Independent assay work has challenged whether it reproduces BDNF-like TrkB activation.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Reproducible benefit on everyday function in the intended population
- Long-term safety and clinically important interactions
- Equivalence of nonstandard products to research formulations
Side effects & risks
- Human long-term exposure, endocrine effects and interactions are inadequately established.
- A naturally occurring flavonoid structure does not certify safety or receptor selectivity.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceThe evidence is cellular and animal. Both favorable mouse findings and mechanism-replication concerns matter; neither establishes clinical efficacy.
Studies
Original proposed TrkB mechanism and preclinical findings.
Alzheimer mouse-model synaptic and memory experiments.
Primary receptor-assay and pharmacology investigation challenging BDNF-like activity.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
7,8-Dihydroxyflavone is not an FDA-approved treatment for the cognitive or mood uses discussed here. Regional use, historical trials and online availability are separate from U.S. drug approval.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Reproducible benefit on everyday function in the intended population
- Long-term safety and clinically important interactions
- Equivalence of nonstandard products to research formulations
Summary
Uncertainty about the mechanism and lack of established human outcomes prevent confident clinical claims.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedA selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone.
Original proposed TrkB mechanism and preclinical findings.
- pubmed7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease.
Alzheimer mouse-model synaptic and memory experiments.
- journalIndependent testing of proposed small-molecule TrkB agonists
Primary receptor-assay and pharmacology investigation challenging BDNF-like activity.